Regeneron Pharmaceuticals Inc. sell Bank of America Co.
Summary
This prediction ended on 30.03.24 with a price of €902.40. The prediction closed with a disappointing performance of 19.37%. Bank_of_America_Co_ has a follow-up prediction for Regeneron Pharmaceuticals Inc., but this time predicts that Regeneron Pharmaceuticals Inc. is a Buy. Bank_of_America_Co_ has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | -3.935% | -3.935% | 12.556% | -13.145% |
| iShares Core DAX® | 1,60 % | 5,04 % | 3,87 % | 50,23 % |
| iShares Nasdaq 100 | 3,74 % | 14,95 % | 36,14 % | 101,08 % |
| iShares Nikkei 225® | 3,74 % | 13,89 % | 43,81 % | 69,38 % |
| iShares S&P 500 | 1,82 % | 8,88 % | 25,51 % | 70,97 % |
Comments by Bank_of_America_Co_ for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
In the thread Trading Regeneron Pharmaceuticals Inc.
Current prediction by Bank_of_America_Co_ for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
07.01.26
07.01.27
05.05.26
Stopped prediction by Bank_of_America_Co_ for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
17.04.25
17.04.26
18.04.26
Regeneron Pharmaceuticals Inc.
12.04.24
12.04.25
13.04.25

